1. SHP:LSE

    Shire PLC

    GBp

    5,635

    Today's change

    135.00 / +2.45%

    1 year change

    +63.76%

    As of May 27 2015 16:59 BST. Data delayed by at least 15 minutes.

Search for Shire PLC and
  1. May 19, 2015

    Circassia £275m fundraising signals revival of UK biotech sector

    When Circassia launched a £275m fundraising last week to finance two acquisitions, the Oxford-based drug developer advanced...

  2. April 30, 2015

    Weak euro lifts European drugmakers

    Sanofi and Bayer reported strong first-quarter results and raised guidance for the full year on Thursday, as drugmakers in...

  1. April 10, 2015

    FTSE 100 closes at record high, buoyed by M&A

    The FTSE 100 set a record closing high on Friday, completing a week dominated by a blockbuster deal in the energy sector,...

  2. March 27, 2015

    Shire shines on fourth day of FTSE falls

    Shire was among the outperformers as the FTSE 100 drifted to its fourth straight decline. Drugmaker Shire gained 2.2 per...

  3. March 26, 2015

    Actavis rewrites ‘big pharma’ playbook

    Move over GlaxoSmithKline. There is a new pharmaceuticals giant in town. After completing its $70bn acquisition of Botox...

  4. March 10, 2015

    Shire shines during sharp FTSE sell-off

    Shire was among the few gainers as the FTSE 100 recorded its sharpest daily fall in five months. Cowen & Co advised clients...

  5. FT Alphaville

    March 5, 2015

    FirstFT (the new 6am Cut)

    You can sign up to receive the email here. China’s ersatz parliament, the National People’s Congress, kicked off today. The...

  6. February 25, 2015

    Pharmacyclics considers $19bn sale

    Pharmacyclics is considering a sale that could value the US cancer drugs maker at about $19bn, according to people familiar...

  7. February 22, 2015

    Valeant agrees to buy Salix for $14.5bn

    Valeant, the serial pharmaceuticals dealmaker, has agreed to buy Salix in an all-cash transaction that values the...

  8. February 15, 2015

    Shire has ‘nothing to hide’ on tax, says chief

    Shire’s chief executive has defended the company’s tax arrangements after being identified as one of the beneficiaries of...

  9. February 15, 2015

    Monday interview: Flemming Ornskov, Shire CEO

    One evening early last October, Flemming Ornskov, chief executive of Shire, had dinner with the man who was supposed to...

  10. February 12, 2015

    Shire says $1.6bn windfall from AbbVie is tax-free

    Shire has been advised that the $1.6bn “break fee” received from AbbVie after the collapse of their abortive merger is not...

  11. February 12, 2015

    Two’s a duopoly, three’s awkward for Kirstie, Phil and Zoopla

    Kirstie Allsopp: Welcome to Disruption, Disruption, Disruption, the property show for estate agents. Phil Spencer: Today...

  12. February 11, 2015

    M&A helps lift US healthcare stocks

    Gilead Sciences, the biotech behemoth that has seen its market valuation soar to a cool $145bn, has put in a strong...

  13. February 1, 2015

    Shire gets go ahead to market binge-eating medicine

    Shire has received its second important regulatory breakthrough in two weeks after winning US approval for the first...

  14. January 12, 2015

    Shire: details matter

    Announcing its $5.2bn purchase of NPS Pharma, Shire said it “expects that the transaction will deliver return on invested...

  15. January 12, 2015

    NPS prospects dependent on drug approval

    Shire’s $5.2bn acquisition of NPS Pharmaceuticals on Sunday was the latest example of a larger drugmaker making a big gamble...

  16. January 12, 2015

    Fresh round of M&A sweeps pharma sector

    Another round of mergers and acquisitions is sweeping the pharmaceuticals sector, in a sign that last year’s boom in...

  17. FT Alphaville

    January 12, 2015

    FirstFT

    A show of unity in Paris, an AirAsia black box and Apple’s secret door More than 3.7m marched in Paris and across France in...

  18. FT Alphaville

    January 12, 2015

    FirstFT (the new 6am cut)

    Read the email in full below or sign up to receive it here. More than 3.7m marched in Paris and across France in a display...

  19. January 11, 2015

    Shire in $5.2bn deal for US biotech NPS

    Shire, Britain’s third-largest drugmaker by market value, has made its biggest ever acquisition with a $5.2bn deal for US...

  20. January 7, 2015

    Pharma takeover battles boost FTSE 100 performance

    Two companies at the centre of takeover battles had the biggest positive impact on the performance of the FTSE 100 last...

  21. January 1, 2015

    Corporate chiefs’ predictions for 2015

    What do corporate chiefs expect in 2015? FT journalists gather predictions, hopes and fears from the UK and elsewhere....

  22. December 22, 2014

    Takeover volumes move to highest post-crisis levels

    Corporate takeover deals surged to their highest levels since the financial crisis this year, with merger and acquisition...

  23. December 14, 2014

    Bank traders lose big on AbbVie-Shire bets

    City of London trading desks at several big investment banks lost money after the collapse of AbbVie’s $54bn takeover offer...

  24. December 11, 2014

    Investors warm to Shire’s independence

    Two months after a bid from AbbVie collapsed, investors have been feeling more comfortable with the idea of Shire staying...

  25. December 8, 2014

    PwC sold ‘tax avoidance on industrial scale’

    MPs accused a firm of accountants of “selling tax avoidance on an industrial scale” on Monday after a tense parliamentary...

  26. November 10, 2014

    Bets gone awry push John Paulson event-driven fund to loss

    John Paulson’s $3bn event-driven hedge fund swung to a 14 per cent loss last month as the investor known for making billions...

  27. November 4, 2014

    Ackman gains ground in fight to force Allergan to sell to Valeant

    Bill Ackman chalked up a big victory in his battle to force Allergan, the maker of blockbuster wrinkle treatment Botox, to...

  28. October 31, 2014

    Boardroom trades November 1

    Matthew Emmens sold shares in Shire as he stepped down as chairman of the pharmaceutical group in March. The shares went...

  29. October 26, 2014

    Right financial officer for the right era

    A new man for a new era. That seems to be the mantra of a series of British companies that are looking to replace their...

  30. October 24, 2014

    Shire and AstraZeneca show standalone strength

    Britain’s number two and three drugmakers burnished their strength as independent companies on Friday when Shire reported...

  31. October 22, 2014

    AbbVie and HP: corporate writing stinks and the CEO is to blame

    AbbVie, the US drugs company, no longer wants to take over Shire, a UK counterpart. Richard Gonzalez, AbbVie’s chief...

  32. October 21, 2014

    Shire interim CFO jumps ship for Severn Trent

    Shire has lost its interim chief financial officer to Severn Trent, increasing the upheaval surrounding the UK-listed...

  33. October 20, 2014

    AbbVie hits at Treasury as Shire deal dies

    The head of AbbVie, which last week dropped its support for a $55bn takeover of UK drugmaker Shire, slammed the US Treasury...

  34. October 19, 2014

    Long-term reforms of US tax system required to stop ‘deserters’

    Spare a thought for the poor US multinational. It has had a horrible time lately and been called lots of beastly names. Back...

  35. October 19, 2014

    M&A deal failure at highest since 2008

    The value of deals that fail to complete has reached its highest level since 2008, in the latest sign that the best year for...

  36. October 17, 2014

    Pfizer’s AstraZeneca pursuit knocked by Shire deal collapse

    The chances of Pfizer reviving its pursuit of AstraZeneca have been greatly diminished after the collapse of AbbVie’s £32bn...

  37. October 16, 2014

    Tax changes roil inversion deals

    The sudden collapse of AbbVie’s proposed $54bn takeover of rival drugmaker Shire does not necessarily signal that the Obama...

  38. October 16, 2014

    When shares fall off a cliff, deal-doers are left running on thin air

    All battle plans evaporate on contact with the enemy, which for City deal-doers is a slumping equities market. A 10 per cent...

Search for Shire PLC and

RELATED VIDEOS

Videos from FT.com that closely match this topic

  1. Lex on why tax inversions are losing their appeal...
    October 15, 2014

    Lex on why tax inversions are losing their appeal